Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 346.43% from the stock’s previous close.

A number of other research firms have also commented on PYXS. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Up 4.7 %

Shares of PYXS stock opened at $1.12 on Wednesday. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The stock has a market cap of $66.60 million, a P/E ratio of -1.09 and a beta of 1.11. The business has a fifty day simple moving average of $1.33 and a 200-day simple moving average of $2.38.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. On average, sell-side analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its stake in shares of Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after purchasing an additional 1,043,228 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at about $1,405,000. Ridgeback Capital Investments L.P. acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at about $560,000. State Street Corp lifted its stake in shares of Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at about $228,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.